Compare PIPR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | DNTH |
|---|---|---|
| Founded | 1895 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2003 | 2018 |
| Metric | PIPR | DNTH |
|---|---|---|
| Price | $69.19 | $82.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 18 |
| Target Price | $79.38 | ★ $139.06 |
| AVG Volume (30 Days) | 791.6K | ★ 876.1K |
| Earning Date | 10-30-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | ★ 54.49 | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $1,904,217,000.00 | $2,036,000.00 |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $12.40 | N/A |
| P/E Ratio | $35.89 | ★ N/A |
| Revenue Growth | ★ 24.33 | N/A |
| 52 Week Low | $61.35 | $32.28 |
| 52 Week High | $309.45 | $117.88 |
| Indicator | PIPR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 47.79 |
| Support Level | $61.35 | $81.16 |
| Resistance Level | $78.49 | $91.36 |
| Average True Range (ATR) | 1.86 | 3.94 |
| MACD | 0.78 | 1.44 |
| Stochastic Oscillator | 95.91 | 87.84 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.